These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients. Kuypers DR; Naesens M; de Jonge H; Lerut E; Verbeke K; Vanrenterghem Y Ther Drug Monit; 2010 Aug; 32(4):394-404. PubMed ID: 20526235 [TBL] [Abstract][Full Text] [Related]
24. Prevention of calcineurin inhibitor nephrotoxicity in renal transplantation. Jacquet A; Francois H; Frangie C; Ahmad L; Charpentier B; Durrbach A Transpl Immunol; 2008 Nov; 20(1-2):29-31. PubMed ID: 18817870 [TBL] [Abstract][Full Text] [Related]
26. Distinct effects of calcineurin dependent and independent immunosuppressants on endotoxaemia-induced nephrotoxicity in rats: Role of androgens. Elzokm SS; Fouda MA; Abdel Moneim RA; El-Mas MM Clin Exp Pharmacol Physiol; 2021 Sep; 48(9):1261-1270. PubMed ID: 34042216 [TBL] [Abstract][Full Text] [Related]
27. The safety of calcineurin inhibitors for kidney-transplant patients. Malvezzi P; Rostaing L Expert Opin Drug Saf; 2015 Oct; 14(10):1531-46. PubMed ID: 26329325 [TBL] [Abstract][Full Text] [Related]
28. Tacrolimus-induced nephrotoxicity and genetic variability: a review. Gijsen VM; Madadi P; Dube MP; Hesselink DA; Koren G; de Wildt SN Ann Transplant; 2012; 17(2):111-21. PubMed ID: 22743729 [TBL] [Abstract][Full Text] [Related]
29. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients. Elens L; van Schaik RH; Panin N; de Meyer M; Wallemacq P; Lison D; Mourad M; Haufroid V Pharmacogenomics; 2011 Oct; 12(10):1383-96. PubMed ID: 21902502 [TBL] [Abstract][Full Text] [Related]
30. Calcineurin inhibitor toxicity in renal allografts: morphologic clues from protocol biopsies. Sharma A; Jain S; Gupta R; Guleria S; Agarwal S; Dinda A Indian J Pathol Microbiol; 2010; 53(4):651-7. PubMed ID: 21045386 [TBL] [Abstract][Full Text] [Related]
32. A comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily cyclosporine on renal function in healthy volunteers. Zaltzman JS Transplantation; 2010 Dec; 90(11):1185-91. PubMed ID: 21166111 [TBL] [Abstract][Full Text] [Related]
34. Understanding the genetic basis for adverse drug effects: the calcineurin inhibitors. Bai JP; Lesko LJ; Burckart GJ Pharmacotherapy; 2010 Feb; 30(2):195-209. PubMed ID: 20099993 [TBL] [Abstract][Full Text] [Related]
35. Smooth muscle-specific actin levels in the urine of renal transplant recipients: correlation with cyclosporine or tacrolimus nephrotoxicity. Haas M; Meehan SM; Josephson MA; Wit EJ; Woodle ES; Thistlethwaite JR Am J Kidney Dis; 1999 Jul; 34(1):69-84. PubMed ID: 10401019 [TBL] [Abstract][Full Text] [Related]
36. Calcineurin inhibitor nephrotoxicity: a review and perspective of the evidence. Issa N; Kukla A; Ibrahim HN Am J Nephrol; 2013; 37(6):602-12. PubMed ID: 23796509 [TBL] [Abstract][Full Text] [Related]
37. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Hesselink DA; van Schaik RH; van der Heiden IP; van der Werf M; Gregoor PJ; Lindemans J; Weimar W; van Gelder T Clin Pharmacol Ther; 2003 Sep; 74(3):245-54. PubMed ID: 12966368 [TBL] [Abstract][Full Text] [Related]
38. Immunosuppressant-induced nephropathy: pathophysiology, incidence and management. Olyaei AJ; de Mattos AM; Bennett WM Drug Saf; 1999 Dec; 21(6):471-88. PubMed ID: 10612271 [TBL] [Abstract][Full Text] [Related]